Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NovoTTF-200A and Pembrolizumab in Melanoma Brain Metastasis
NCT04129515Phase 2Withdrawn
- Sponsor
- Brown University
- Start
- Oct 2025
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 2, open-label trial in melanoma brain metastasis (MBM) (2 arms), sponsored by Brown University. Primary endpoint: Dose Limiting Toxicity at 21 days. Planned start Oct 2025; status: withdrawn.
02
Conditions
melanoma brain metastasis (MBM)
Beyond the preview
Go deeper on NCT04129515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04129515.